Primary sclerosing cholangitis: what is new in the therapeutic landscape

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease affecting the intra- and extra-hepatic bile ducts, leading to progressive inflammation and fibrosis. Its pathogenesis is complex and involves genetic predisposition, environmental triggers, and their interaction throug...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Current opinion in immunology Ročník 96; s. 102613
Hlavní autoři: Curto, Armando, Cristoferi, Laura, Carbone, Marco, Galli, Andrea, Invernizzi, Pietro
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 01.10.2025
Témata:
Animals
Cholangitis, Sclerosing - diagnosis
Cholangitis, Sclerosing - etiology
Cholangitis, Sclerosing - immunology
Cholangitis, Sclerosing - therapy
Gastrointestinal Microbiome
Humans
Liver Transplantation
ISSN:0952-7915, 1879-0372, 1879-0372
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease affecting the intra- and extra-hepatic bile ducts, leading to progressive inflammation and fibrosis. Its pathogenesis is complex and involves genetic predisposition, environmental triggers, and their interaction through the gut–liver axis, mediated by the microbiota. To date, no approved therapies modify the natural history of PSC, and liver transplantation remains the only curative option. This review provides an overview of current investigational therapies for PSC, emphasizing their mechanisms of action and relevance to the underlying disease biology. It also examines key challenges in therapeutic development, including the lack of validated surrogate end points, clinical heterogeneity, and the confounding effects of concomitant inflammatory bowel disease treatments factors that complicate trial design and interpretation. Clarifying these aspects is essential to support the development of effective, targeted therapies for this complex and currently untreatable condition.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0952-7915
1879-0372
1879-0372
DOI:10.1016/j.coi.2025.102613